Pharmacotherapy of Pulmonary Hypertension

This volume focuses on current evidence-based pharmacological treatments of various forms of pulmonary hypertension and provides a comprehensive review of the latest developments in this area. The first part of the book covers the definition, classification, pathophysiology, pathology, biomarkers and animal models of the disease, thus laying the conceptual basis for what follows. The middle section provides an overview of the established therapies, such as calcium channel blockers, prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors and inhaled nitric oxide. The last section explores novel pathways and emerging therapeutic approaches including soluble guanylate cyclase stimulators, Rho-kinase inhibitors, inhibitors of serotonin receptors and transporters, peptide growth factors, vasoactive peptides, modulators of redox equilibrium and cyclic nucleotide homeostasis, as well as immunosuppressive and anti-proliferative agents. Particular attention is given to the clinical applications of these experimental therapies, that are on the horizon. The book thus spans the continuum from basic science to clinical applications.

• Vasoactive substances
• WHO Group I-V
• lung vasculature
• pulmonary artery
• pulmonary hypertension (PH)
• pulmonary vein

• Faculte´ de Me´decine, Univ Paris-Sud, Le Kremlin Bicêtre, France

  Marc Humbert

• Dep of Anasthesia and Critical Care, Harvard Medical School Massachusetts General Hospital, Boston, USA

  Oleg V. Evgenov

• Cardiovascular Research, Bayer Pharma AG, Wuppertal, Germany

  Johannes-Peter Stasch

Policies and ethics